Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Piero Dalerba
Columbia University Health Sciences, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Amgen
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Dalerba will be supervising (b)(6), a PhD student supported by this TL1 award. (b)(6) research project is aimed at understanding the molecular mechanisms that underlie colon cancer resistance to anti-EGFR monoclonal antibodies. One of the two monoclonal antibodies investigated in this project (panitumumab) is a clinically approved drug, manufactured and sold by Amgen.
Dr. Dalerba's financial interests in Amgen are imputed to him from his spouse, who is an Amgen employee; she holds a position as (b)(6), and she is not involved in management decisions related to panitumumab, nor does her work relate to Dr. Dalerba's Columbia research. In light of this Amgen connection and other facts, Columbia found that Dr. Dalerba's significant financial interest in Amgen (imputed to him through his spouse) could affect the design, conduct, or reporting of the research, though found a limited risk of bias and a manageable conflict.
NRSA Training Core
NA
Filed on September 01, 2017.
Tell us what you know about Piero Dalerba's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Piero Dalerba”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Piero Dalerba | Columbia University Health Sciences | Conflict of Interest | Amgen | $200,000 - $249,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.